Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent Lymphoma
This clinical trial update notes a multicenter retrospective observational study evaluating relapsed Diffuse Large B-Cell Lymphoma presentin…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL [Phase 2]
A Phase 2 clinical trial evaluating Relmacabtagene autoleucel as second-line therapy for adults with aggressive B-cell non-Hodgkin lymphomas…
-
CLINICAL_TRIALS research · 2025-02-10Clinical Trial Update: Telehealth-based Symptom Management for Veterans Treated With Selinexor
ClinicalTrials.gov update indicates a telehealth-based symptom management study for veterans treated with selinexor is currently active but …
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma [Phase 1]
A Phase 1 trial assessing sequential administration of CD19 CAR-NK cells followed by 7x19 CAR-T cells in relapsed/refractory B-cell lymphoma…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma [NA]
A prospective analysis of circulating nucleosomes in patients receiving first-line treatment for non-Hodgkin lymphoma, including Follicular …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-04Clinical Trial Update: Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL [Phase 2]
This is a Phase 2 clinical trial evaluating a three-drug regimen of polatuzumab vedotin, rituximab, and orelabrutinib for elderly, frail pat…
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
An Italian multicenter retrospective observational study evaluating the clinical characteristics and outcomes of relapsed or refractory diff…
-
CLINICAL_TRIALS research · 2025-01-28Clinical Trial Update: Immunotherapy in Lymphoma
An ongoing immunotherapy trial for relapsed or refractory B-cell lymphomas is currently recruiting. The study targets high-grade B-cell lymp…
-
CLINICAL_TRIALS research · 2025-01-24Clinical Trial Update: Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 3]
Phase 3 clinical trial assessing BEBT-908 plus Rituximab-based standard of care versus standard of care in relapsed/refractory diffuse large…
-
CLINICAL_TRIALS research · 2025-01-23Clinical Trial Update: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 3]
A Phase 3 clinical trial update evaluating change in disease activity when subcutaneous epcoritamab is added to R-CHOP versus R-CHOP alone i…
-
CLINICAL_TRIALS research · 2025-01-20Clinical Trial Update: An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
This clinical trial update notes an Italian multicenter retrospective observational study evaluating the effectiveness and safety of combini…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines
This clinical trial investigates the role of spectral CT in evaluating cardiotoxicity from anthracycline therapy in patients with Hodgkin ly…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update on locally manufactured CAR T-cell products for multiple B-cell malignancies, including B-cell lymphoma and B-…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients
Clinical trial update indicates pixantrone as bridging therapy to allogeneic transplant or CAR-T cell therapy in patients with diffuse large…
-
CLINICAL_TRIALS research · 2025-01-01Clinical Trial Update: PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
A clinical trial exploring Granzyme B–targeted PET imaging to predict immunotherapy efficacy in diffuse large B-cell lymphoma, currently rec…
-
CLINICAL_TRIALS research · 2024-12-30Clinical Trial Update: CR-CHOP+X in Previously Untreated DEL [Phase 2]
Phase 2 trial investigating CR-CHOP+X in patients with previously untreated diffuse large B-cell lymphoma (DEL), currently RECRUITING.
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) [Phase 2]
A Phase 2 clinical trial update evaluating the CD-RCHOP regimen in newly diagnosed diffuse large B-cell lymphoma with TP53 mutation and 17p …
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: Dynamic CtDNA-guided Targeted Therapy in DLBCL [Phase 2]
A Phase 2 clinical trial evaluating dynamic ctDNA-guided targeted therapy in diffuse large B-cell lymphoma is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: Real-World Study of DLBCL With Different Genetic Subtypes
A real-world study of diffuse large B-cell lymphoma across different genetic subtypes is currently recruiting.
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma [Phase 2]
Phase 2 clinical trial update of GPL in patients with relapsed/refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: The Microbiome in Blood Cancer and HLH
A clinical trial update from University of Nottingham examining the microbiome's role in blood cancers and haemophagocytic lymphohistiocytos…
-
CLINICAL_TRIALS research · 2024-12-10Clinical Trial Update: realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
This ClinicalTrials.gov entry describes the realMIND observational study evaluating the safety and effectiveness of Tafasitamab in combinati…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
The PREDIC-TO study is currently recruiting to investigate thrombosis in patients with Diffuse Large B-Cell Lymphoma.
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL [Phase 2]
Phase 2 trial evaluating the RLC regimen followed by CR-CHOP in elderly patients with newly diagnosed double-expressor lymphoma. The study s…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Obutinib or Decitabine in combination with Rituximab, Cyclophosphamide, and Prednisone as the primary …